Antiproliferative and antiangiogenic effects of zerumbone from Zingiber zerumbet L. Smith in sprague dawley rat model of hepatocellular carcinoma

Nozlena Abdul Samad; Ahmad Bustamam Abdul; Heshu Sulaiman Rahman; Rasedee Abdullah; Tengku Azmi Tengku Ibrahim; Hemn Hassan Othman

Articles

Abstract

Pharmacognosy Magazine ,2019,15,61,277-282.

DOI:10.4103/pm.pm_118_18

Published:March 2019

Type:Original Article

Authors:

Author(s) affiliations:

Nozlena Abdul Samad¹, Ahmad Bustamam Abdul², Heshu Sulaiman Rahman³, Rasedee Abdullah⁴, Tengku Azmi Tengku Ibrahim⁴, Hemn Hassan Othman⁵
¹Integrative Medicine Cluster, Sains@BERTAM, Advanced Medical and Dental Institute, Universiti Sains Malaysia, Kepala Batas, Penang; Cancer Research Laboratory, Institute of Bioscience, Universiti Putra Malaysia, Serdang, Selangor, Malaysia
²Cancer Research Laboratory, Institute of Bioscience, Universiti Putra Malaysia, Serdang, Selangor, Malaysia
³Department of Clinic and Internal Medicine, College of Veterinary Medicine, University of Sulaimani; Department of Medical Laboratory Sciences, College of Science, Komar University of Science and Technology, Sulaimani City, Iraq; Department of Cell and Molecular Biology, Faculty of Biotechnology and Biomolecular Sciences, Universiti Putra Malaysia, Serdang, Selangor, Malaysia
⁴Department of Microbiology and Pathology, Faculty of Veterinary Medicine, Universiti Putra Malaysia, Serdang, Selangor, Malaysia
⁵Department of Veterinary Pathology and Microbiology, Faculty of Veterinary Medicine, Universiti Putra Malaysia, Serdang, Selangor, Malaysia; Department of Anatomy and Pathology, College of Veterinary Medicine, University of Sulaimani, Sulaimani City, Iraq

Abstract:

Context: Zerumbone (ZER) is known to exhibit anticancer properties on various cancer cells both in vitro and in vivo. However, the anti-angiogenesis effect of ZER on liver cancers in vivo is not yet addressed clearly. Aims: This study aimed to investigate the in vivo antiproliferative and antiangiogenesis effects of ZER using rats with diethylnitrosamine-induced hepatocellular carcinoma (HCC). Materials and Methods: The antiproliferative and anti-angiogenesis effects of ZER were determined using the hepatosomatic index, vascular endothelial growth factor (VEGF) immunoassay, terminal deoxynucleotidyl transferase dUTP nick end labeling assay, histopathology, and immunohistochemistry analysis. Results: Nontreated rats with HCC had higher median liver weight than those treated with ZER or suramin. The expression of VEGF, matrix metalloprotease, and Ki-67 that were high in nontreated HCC rats was down-regulated with ZER or suramin treatments. Statistical Analysis Used: Statistical analyses were performed using the Statistical Package for Social Science version 21.0 (SPSS Inc, IBM, Maryland, USA). The data were expressed as the mean ± standard deviation and analyzed using a one-way analysis of variance. P < 0.05 was considered statistically significant. Conclusion: ZER has the potential to be developed as the pro-apoptotic and antiangiogenic agent in the treatment of HCC.